A-FLUX Reducer System® enters U.S. clinical evaluation in the SERRA-I early feasibility studySANTA CLARA, Calif., June 17, 2026 /PRNewswire/ — VahatiCor, Inc., a medtech company developing interventional therapies for coronary microvascular dysfunction (CMD), today announced the enrollment of…

Read the full release →

News provided by PR Newswire.